Each year, in Canada, approximately 3,100 women are diagnosed with ovarian cancer. Unfortunately, in 2023, it is estimated that 1,950 Canadian women will die from the disease.

Although the term “ovarian cancer” is often used in the singular form, it is essential to understand that this disease actually comes in various forms, determined by the cells affected. This diversity is also reflected in responses to treatments, not all of which are yet sufficiently effective or appropriate.

In response to this complex reality, Ovarian Cancer Canada (OCC) and the Cancer Research Society (CRS) jointly announce the launch of the “Bridging the Gap for Ovarian Cancer Treatments Grants Competition”. This strategic partnership mobilizes a significant amount of $1.2 million to fund two research projects of $600,000 each over a three-year period.

This strategic partnership mobilizes a significant amount of $1.2 million to fund two research projects of $600,000 each over a three-year period.

This competition represents a major advancement, by specifically directing funding towards translational and clinical research projects. These projects will aim to improve and expand treatment options for women diagnosed with all types of ovarian cancer. Special attention will also be given to studies exploring treatments for rare types of ovarian cancer, which generally do not respond to standard treatments and have limited long-term survival prospects.

By joining forces through exceptional partnerships, such as this one with our valued partner CRS, we aim to turn each contribution into a powerful driver for cancer research. This collaboration considerably amplifies our global impact in outsmarting ovarian cancer.